Top Markets
Coin of the day
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Rang in aandelen #5731
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aandeelprijs
$29.86
Laatst gesynchroniseerd: 2026-08-19
Marktkapitalisatie
$2.48B
Verandering (1 dag)
4.92%
Verandering (1 jaar)
502.82%
Land
TW
Handel Lin BioScience, Inc. (6696)

Categorie

Dividendrendementgeschiedenis voor Lin BioScience, Inc. (6696)
Het dividendrendement (TTM) van Lin BioScience, Inc. (aandelsymbool: 6696) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Lin BioScience, Inc. (6696) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH